Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2021

10.11.2020 | Pancreatic Tumors

Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis

verfasst von: Wilson Luiz da Costa Jr., MD, MPH, PhD, Hop S. Tran Cao, MD, Kyle H. Sheetz, MD, MSc, Xiangjun Gu, PhD, Edward C. Norton, PhD, Nader N. Massarweh, MD, MPH

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Neoadjuvant therapy (NAT) is increasingly being used in the management of patients with resectable pancreatic ductal adenocarcinoma (PDAC); however, there is a lack of evidence regarding the benefit among these patients.

Objective

The aim of this study was to evaluate overall survival (OS) in PDAC patients with resectable disease treated with NAT or upfront resection through instrumental variable (IV) analysis.

Design

A national cohort study of resectable PDAC patients in the National Cancer Data Base (2007–2015) treated with either upfront surgery or resection after NAT. Using multivariable modeling and IV methods, OS was compared between those treated with NAT and upfront resection. The IV was hospital-level NAT utilization in the most recent year prior to treatment.

Results

The cohort included 16,666 patients (14,012 upfront resection; 2654 NAT) treated at 779 hospitals. Among those treated with upfront resection, 59.9% received any adjuvant therapy. NAT patients had higher median (27.9 months, 95% confidence interval [CI] 26.2–29.1) and 5-year OS (24.1%, 95% CI 21.9–26.3%) compared with those treated with upfront surgery (median 21.2 months, 95% CI 20.7–21.6; 5-year survival 20.9%, 95% CI 20.1–21.7%). After multivariable modeling, NAT was associated with an approximately 20% decrease in the risk of death (hazard ratio [HR] 0.78, 95% CI 0.73–0.84), and this effect was magnified in the IV analysis (HR 0.61, 95% CI 0.47–0.79).

Conclusions

In patients with resectable PDAC, NAT is associated with improved survival relative to upfront resection. Given the benefits of multimodality therapy and the challenges in receiving adjuvant therapy, consideration should be given to treating all PDAC patients with NAT.
Literatur
1.
Zurück zum Zitat Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2018. https://gco.iarc.fr/today. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2018. https://​gco.​iarc.​fr/​today.
3.
Zurück zum Zitat Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–8.CrossRef Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–8.CrossRef
4.
Zurück zum Zitat Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG, 3rd, Roman SA, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127–32.CrossRef Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG, 3rd, Roman SA, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127–32.CrossRef
5.
Zurück zum Zitat Mirkin KA, Hollenbeak CS, Gusani NJ, Wong J. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Am J Surg. 2017;214(1):80–8.CrossRef Mirkin KA, Hollenbeak CS, Gusani NJ, Wong J. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Am J Surg. 2017;214(1):80–8.CrossRef
6.
Zurück zum Zitat Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.CrossRef Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.CrossRef
7.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRef Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRef
8.
Zurück zum Zitat Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRef Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRef
9.
Zurück zum Zitat Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33–45.CrossRef Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33–45.CrossRef
10.
Zurück zum Zitat Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G, 2nd, et al. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 2017;162(3):557–67.CrossRef Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G, 2nd, et al. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 2017;162(3):557–67.CrossRef
11.
Zurück zum Zitat Nathan H, Atoria CL, Bach PB, Elkin EB. Hospital volume, complications, and cost of cancer surgery in the elderly. J Clin Oncol. 2015;33(1):107–14.CrossRef Nathan H, Atoria CL, Bach PB, Elkin EB. Hospital volume, complications, and cost of cancer surgery in the elderly. J Clin Oncol. 2015;33(1):107–14.CrossRef
12.
Zurück zum Zitat Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.CrossRef Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.CrossRef
13.
Zurück zum Zitat Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. Epub 5 Apr 2019. https://doi.org/10.1097/sla.0000000000003284. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. Epub 5 Apr 2019. https://​doi.​org/​10.​1097/​sla.​0000000000003284​.
14.
Zurück zum Zitat Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22.CrossRef Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22.CrossRef
15.
Zurück zum Zitat Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy With FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9.CrossRef Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy With FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9.CrossRef
16.
Zurück zum Zitat Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.CrossRef Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.CrossRef
18.
Zurück zum Zitat Fisher AV, Abbott DE, Venkatesh M, Leverson GE, Campbell-Flohr SA, Ronnekleiv-Kelly SM, et al. The impact of hospital neoadjuvant therapy utilization on survival outcomes for pancreatic cancer. Ann Surg Oncol. 2018;25(9):2661–8.CrossRef Fisher AV, Abbott DE, Venkatesh M, Leverson GE, Campbell-Flohr SA, Ronnekleiv-Kelly SM, et al. The impact of hospital neoadjuvant therapy utilization on survival outcomes for pancreatic cancer. Ann Surg Oncol. 2018;25(9):2661–8.CrossRef
19.
Zurück zum Zitat da Costa WL Jr, Tran Cao HS, Massarweh NN. Neoadjuvant treatment for patients with localized pancreatic adenocarcinoma—are we there yet? JAMA Oncol. 2020;6(8):1163–4.CrossRef da Costa WL Jr, Tran Cao HS, Massarweh NN. Neoadjuvant treatment for patients with localized pancreatic adenocarcinoma—are we there yet? JAMA Oncol. 2020;6(8):1163–4.CrossRef
20.
Zurück zum Zitat Satoi SUM, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, et al. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05). J. Clin. Oncol. 2019;37(15 Suppl):4126.CrossRef Satoi SUM, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, et al. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05). J. Clin. Oncol. 2019;37(15 Suppl):4126.CrossRef
21.
Zurück zum Zitat Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.CrossRef Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.CrossRef
22.
Zurück zum Zitat Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34.CrossRef Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34.CrossRef
23.
Zurück zum Zitat Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):278–85.CrossRef Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):278–85.CrossRef
24.
Zurück zum Zitat Urbach DR. Pledging to eliminate low-volume surgery. N Engl J Med. 2015;373(15):1388-90.CrossRef Urbach DR. Pledging to eliminate low-volume surgery. N Engl J Med. 2015;373(15):1388-90.CrossRef
25.
Zurück zum Zitat Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531–43.CrossRef Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531–43.CrossRef
26.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRef Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRef
27.
Zurück zum Zitat Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–56.CrossRef Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–56.CrossRef
28.
Zurück zum Zitat Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–94.CrossRef Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–94.CrossRef
29.
Zurück zum Zitat Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045–53.CrossRef Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045–53.CrossRef
30.
Zurück zum Zitat Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37.CrossRef Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37.CrossRef
31.
Zurück zum Zitat El Amrani M, Clement G, Lenne X, Farges O, Delpero JR, Theis D, et al. Failure-to-rescue in patients undergoing pancreatectomy: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients. Ann Surg. 2018;268(5):799–807.CrossRef El Amrani M, Clement G, Lenne X, Farges O, Delpero JR, Theis D, et al. Failure-to-rescue in patients undergoing pancreatectomy: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients. Ann Surg. 2018;268(5):799–807.CrossRef
32.
Zurück zum Zitat Amini N, Spolverato G, Kim Y, Pawlik TM. Trends in hospital volume and failure to rescue for pancreatic surgery. J Gastrointest Surg. 2015;19(9):1581–92.CrossRef Amini N, Spolverato G, Kim Y, Pawlik TM. Trends in hospital volume and failure to rescue for pancreatic surgery. J Gastrointest Surg. 2015;19(9):1581–92.CrossRef
33.
Zurück zum Zitat Sheetz KH, Dimick JB, Nathan H. Centralization of high-risk cancer surgery within existing hospital systems. J Clin Oncol. 2019;37(34):3234–42.CrossRef Sheetz KH, Dimick JB, Nathan H. Centralization of high-risk cancer surgery within existing hospital systems. J Clin Oncol. 2019;37(34):3234–42.CrossRef
34.
Zurück zum Zitat Jacobs RC, Groth S, Farjah F, Wilson MA, Petersen LA, Massarweh NN. Potential impact of “take the volume pledge” on access and outcomes for gastrointestinal cancer surgery. Ann Surg. 2019;270(6):1079–89.CrossRef Jacobs RC, Groth S, Farjah F, Wilson MA, Petersen LA, Massarweh NN. Potential impact of “take the volume pledge” on access and outcomes for gastrointestinal cancer surgery. Ann Surg. 2019;270(6):1079–89.CrossRef
35.
Zurück zum Zitat Du L, Wang-Gillam A. Trends in neoadjuvant approaches in pancreatic cancer. J Natl Compr Cancer Netw. 2017;15(8):1070–7.CrossRef Du L, Wang-Gillam A. Trends in neoadjuvant approaches in pancreatic cancer. J Natl Compr Cancer Netw. 2017;15(8):1070–7.CrossRef
36.
Zurück zum Zitat Baugh KA, Tran Cao HS, van Buren G 2nd, Silberfein EJ, Hsu C, Chai C, et al. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery. 2019;165(2):307–14.CrossRef Baugh KA, Tran Cao HS, van Buren G 2nd, Silberfein EJ, Hsu C, Chai C, et al. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery. 2019;165(2):307–14.CrossRef
37.
Zurück zum Zitat Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35(29):3330–7.CrossRef Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35(29):3330–7.CrossRef
Metadaten
Titel
Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis
verfasst von
Wilson Luiz da Costa Jr., MD, MPH, PhD
Hop S. Tran Cao, MD
Kyle H. Sheetz, MD, MSc
Xiangjun Gu, PhD
Edward C. Norton, PhD
Nader N. Massarweh, MD, MPH
Publikationsdatum
10.11.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09327-3

Weitere Artikel der Ausgabe 6/2021

Annals of Surgical Oncology 6/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.